134 related articles for article (PubMed ID: 38724041)
1. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
Paller AS; Guide SV; Ayala D; Gonzalez ME; Lucky AW; Bagci IS; Marinkovich MP
J Dermatolog Treat; 2024 Dec; 35(1):2350232. PubMed ID: 38724041
[TBL] [Abstract][Full Text] [Related]
2. Beremagene Geperpavec: First Approval.
Dhillon S
Drugs; 2023 Aug; 83(12):1131-1135. PubMed ID: 37432558
[TBL] [Abstract][Full Text] [Related]
3. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
[TBL] [Abstract][Full Text] [Related]
4. Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.
Tovar Vetencourt A; Sayed-Ahmed I; Gomez J; Chen H; Agostini B; Carroll K; Parry T; Krishnan S; Sabater AL
N Engl J Med; 2024 Feb; 390(6):530-535. PubMed ID: 38324486
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
Epstein AL; Haag-Molkenteller C
Cell; 2023 Aug; 186(17):3523-3523.e1. PubMed ID: 37595560
[TBL] [Abstract][Full Text] [Related]
6. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I; Agarwal P; Zhang P; Dolorito JA; Oliver S; Liu H; Reitze N; Sarma N; Bagci IS; Sridhar K; Kakarla V; Yenamandra VK; O'Malley M; Prisco M; Tufa SF; Keene DR; South AP; Krishnan SM; Marinkovich MP
Nat Med; 2022 Apr; 28(4):780-788. PubMed ID: 35347281
[TBL] [Abstract][Full Text] [Related]
7. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.
Raymakers AJN; Kesselheim AS; Mostaghimi A; Feldman WB
JAMA Dermatol; 2024 Mar; 160(3):297-302. PubMed ID: 38294784
[TBL] [Abstract][Full Text] [Related]
8. Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper.
Doolan BJ; McGrath JA; Mellerio JE
Br J Dermatol; 2024 Feb; 190(3):340-342. PubMed ID: 37936299
[No Abstract] [Full Text] [Related]
9. Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts.
Villavisanis DF; Perrault DP; Kiani SN; Cholok D; Fox PM
J Hand Surg Am; 2024 May; 49(5):472-480. PubMed ID: 38085193
[TBL] [Abstract][Full Text] [Related]
10. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
[TBL] [Abstract][Full Text] [Related]
11. A Case Report of an Infant with Autosomal Recessive Dystrophic Epidermolysis Bullosa: COL7A1 Gene Mutations at C2005T and G7922A.
Liu J; Wang L
Acta Dermatovenerol Croat; 2021 Dec; 29(3):164-166. PubMed ID: 34990346
[TBL] [Abstract][Full Text] [Related]
12. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
[TBL] [Abstract][Full Text] [Related]
13. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
Ito K; Sawamura D; Goto M; Nakamura H; Nishie W; Sakai K; Natsuga K; Shinkuma S; Shibaki A; Uitto J; Denton CP; Nakajima O; Akiyama M; Shimizu H
Am J Pathol; 2009 Dec; 175(6):2508-17. PubMed ID: 19893033
[TBL] [Abstract][Full Text] [Related]
14. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa.
Khan A; Riaz R; Ashraf S; Akilimali A
Ann Med Surg (Lond); 2023 Dec; 85(12):6298-6301. PubMed ID: 38098548
[TBL] [Abstract][Full Text] [Related]
15. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo.
Woodley DT; Keene DR; Atha T; Huang Y; Ram R; Kasahara N; Chen M
Mol Ther; 2004 Aug; 10(2):318-26. PubMed ID: 15294178
[TBL] [Abstract][Full Text] [Related]
16. Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.
Wang X; Alshehri F; Manzanares D; Li Y; He Z; Qiu B; Zeng M; A S; Lara-Sáez I; Wang W
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884578
[TBL] [Abstract][Full Text] [Related]
17. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
18. A novel mutation of COL7A1 in a Chinese DEB-Pt family and review of the literature.
Jin L; Li Z; Xin C; Tang L; Zhang X; Zhang B; Yang S
J Cosmet Dermatol; 2020 Jun; 19(6):1508-1512. PubMed ID: 31709745
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
Dang N; Murrell DF
Exp Dermatol; 2008 Jul; 17(7):553-68. PubMed ID: 18558993
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Hovnanian A
Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
